These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1575173)

  • 1. New developments in sustained-release antihypertensive therapy: formulation and pharmacokinetic considerations.
    Devane JG; Mulligan S; Kavanagh M; Davis SS; Sparrow RA; Wilding IR
    Am J Cardiol; 1992 Apr; 69(13):23E-27E. PubMed ID: 1575173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine.
    Chung M; Reitberg DP; Gaffney M; Singleton W
    Am J Med; 1987 Dec; 83(6B):10-4. PubMed ID: 3503594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.
    Grundy JS; Foster RT
    Clin Pharmacokinet; 1996 Jan; 30(1):28-51. PubMed ID: 8846626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bioavailability of new nifedipine preparations in man. 1. Pharmacokinetics of nifedipine in the form of sustained-release tablets].
    Lutz D; Pabst G; Dahmen W; Molz KH; Jaeger H
    Arzneimittelforschung; 1985; 35(12):1840-2. PubMed ID: 4096741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of nifedipine derived from a new retard tablet formulation.
    Avgerinos A; Gorrod JW
    Eur J Drug Metab Pharmacokinet; 1990; 15(4):273-8. PubMed ID: 2088764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bioequivalence of nifedipine sustained-release formulations in comparison to standard preparations in solid state].
    Herrmann R
    Arzneimittelforschung; 1996 Jan; 46(1):28-34. PubMed ID: 8821514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast.
    Schug BS; Brendel E; Wonnemann M; Wolf D; Wargenau M; Dingler A; Blume HH
    Eur J Clin Pharmacol; 2002 May; 58(2):119-25. PubMed ID: 12012144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation dependent pharmacokinetics--does the dosage form matter for nifedipine?
    Toal CB
    J Cardiovasc Pharmacol; 2004 Jul; 44(1):82-6. PubMed ID: 15175561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical and pharmacokinetic comparison of 2 oral preparations of nifedipine: 10 mg capsules and 20 mg delayed-release tablets].
    Vidal-Gárate J; Castañeda Hernández G; Hoyo Vadillo C; Herrera Abarca JE; Salazar LA; Moreno Ramos A; Fortino Chávez J; Tena I; Hong E
    Arch Inst Cardiol Mex; 1989; 59(1):73-80. PubMed ID: 2486739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers.
    Cainazzo MM; Pinetti D; Savino G; Bartiromo M; Forgione A; Bertolini A
    Drugs Exp Clin Res; 2005; 31(3):115-21. PubMed ID: 16033250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of nifedipine slow-release during sustained tocolysis.
    ter Laak MA; Roos C; Touw DJ; van Hattum PR; Kwee A; Lotgering FK; Mol BW; van Pampus MG; Porath MM; Spaanderman ME; van der Post JA; Papatsonis DN; van 't Veer NE
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):84-91. PubMed ID: 25407260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The kinetics of nifedipine release from porous hydrophilic matrices and the pharmacokinetics in man.
    Leucuta SE
    Pharmazie; 1988 Dec; 43(12):845-8. PubMed ID: 3247376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aiming for steady 24-hour plasma concentrations: a comparison of two calcium antagonist and beta-blocker combinations.
    Eriksson M; Nyberg G; Lidman K; Olofsson B; Bergstrand R
    Blood Press Suppl; 1993; 1():16-21. PubMed ID: 7909705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and bioavailability of a sustained release nifedipine formulation.
    Piovella C
    Arzneimittelforschung; 1987 Jul; 37(7):832-5. PubMed ID: 3675679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of two types of meal on the pharmacokinetics of a modified-release formulation of nifedipine (Adalat Retard).
    Armstrong J; Challenor VF; Macklin BS; Renwick AG; Waller DG
    Eur J Clin Pharmacol; 1997; 53(2):141-3. PubMed ID: 9403286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nifedipine gastrointestinal therapeutic system.
    Swanson DR; Barclay BL; Wong PS; Theeuwes F
    Am J Med; 1987 Dec; 83(6B):3-9. PubMed ID: 3503595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-release compression-coated core tablet containing nifedipine for chronopharmacotherapy.
    Sawada T; Kondo H; Nakashima H; Sako K; Hayashi M
    Int J Pharm; 2004 Aug; 280(1-2):103-11. PubMed ID: 15265551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union.
    Wonnemann M; Schug B; Schmücker K; Brendel E; van Zwieten PA; Blume H
    Int J Clin Pharmacol Ther; 2006 Jan; 44(1):38-48. PubMed ID: 16425970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once daily nifedipine: the formulation dictates the pharmacokinetic characteristics and the therapeutic responses.
    Toal CB; Meredith PA; Elliott HL
    Int J Clin Pharmacol Ther; 2012 Mar; 50(3):202-17. PubMed ID: 22373833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microminipig: A suitable animal model to estimate oral absorption of sustained-release formulation in humans.
    Hamada T; Watanabe Y; Iida K; Sano N; Amano N
    Int J Pharm; 2020 Jun; 584():119457. PubMed ID: 32464228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.